Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lenny Dang

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 29, 2021
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant MalignanciesYue Chen, Nelamangala V Nagaraja, Bin Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activityJosep Domingo-Domenech, Cristina Oliva, Ana Rovira, et al.
The Journal of Experimental Medicine|February 10, 2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsStefan Gross, Rob A Cairns, Mark D Minden, et al.
The Journal of Biological Chemistry|March 27, 2014
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1Mindy I Davis, Stefan Gross, Min Shen, et al.
Haematologica|January 25, 2020
AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypesMinke A E Rab, Brigitte A Van Oirschot, Penelope A Kosinski, et al.
Nature Communications|January 11, 2019
Structure and inhibition mechanism of the catalytic domain of human squalene epoxidaseAnil K Padyana, Stefan Gross, Lei Jin, et al.
JCI Insight|September 7, 2023
Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosisAlessandro Matte, Anand B Wilson, Federica Gevi, et al.
Blood|May 16, 2022
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Z Xu, Anna Conrey, Ingrid Frey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoJaneta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivoTeru Hideshima, Paola Neri, Pierfranchesco Tassone, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 29, 2021
Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant MalignanciesYue Chen, Nelamangala V Nagaraja, Bin Fan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activityJosep Domingo-Domenech, Cristina Oliva, Ana Rovira, et al.
The Journal of Experimental Medicine|February 10, 2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsStefan Gross, Rob A Cairns, Mark D Minden, et al.
The Journal of Biological Chemistry|March 27, 2014
Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1Mindy I Davis, Stefan Gross, Min Shen, et al.
Haematologica|January 25, 2020
AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypesMinke A E Rab, Brigitte A Van Oirschot, Penelope A Kosinski, et al.
Nature Communications|January 11, 2019
Structure and inhibition mechanism of the catalytic domain of human squalene epoxidaseAnil K Padyana, Stefan Gross, Lei Jin, et al.
JCI Insight|September 7, 2023
Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosisAlessandro Matte, Anand B Wilson, Federica Gevi, et al.
Blood|May 16, 2022
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Z Xu, Anna Conrey, Ingrid Frey, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoJaneta Popovici-Muller, Jeffrey O Saunders, Francesco G Salituro, et al.
Pageof 4